Coadministration of Orally Inhaled Zanamivir with Inactivated Trivalent Influenza Vaccine Does Not Adversely Affect the Production of Antihaemagglutinin Antibodies in the Serum of Healthy Volunteers
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 36 (Supplement) , 51-58
- https://doi.org/10.2165/00003088-199936001-00006
Abstract
Objective Zanamivir, a clinically proven potent and specific inhibitor of influenza A and B neuraminidase, has been approved in some countries for the treatment of influenza and is in late-stage...Keywords
This publication has 11 references indexed in Scilit:
- Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.1998
- Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus InfectionsNew England Journal of Medicine, 1997
- Antivirals for Pandemic InfluenzaThe Journal of Infectious Diseases, 1997
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993
- Prophylaxis and Treatment of InfluenzaNew England Journal of Medicine, 1990
- Resistance of Influenza A Virus to Amantadine and Rimantadine: Results of One Decade of SurveillanceThe Journal of Infectious Diseases, 1989
- Reactogenicity, Immunogenicity, and Antibody Persistence in Adults Given Inactivated Influenza Virus Vaccines--1978Clinical Infectious Diseases, 1983
- Summary of Clinical Trials of Inactivated Influenza Vaccine--1978Clinical Infectious Diseases, 1983
- DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MANBritish Medical Bulletin, 1979